Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Other Nuclides: 31P, 19F, 15N NMR01:16

Other Nuclides: 31P, 19F, 15N NMR

372
Many organic, inorganic, and biological molecules contain spin-half nuclei such as nitrogen-15, fluorine-19, and phosphorus-31. As a result, NMR studies of these nuclei have found extensive applications in chemical and biological research.
While fluorine-19 and phosphorous-31 have high natural abundances (100%) and positive gyromagnetic ratios, nitrogen-15 has a low natural abundance and a negative gyromagnetic ratio. However, nitrogen-15 is still preferred over nitrogen-14 (which has a...
372

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multi-modal flow phantom for quantitative PET/Spectral CT.

bioRxiv : the preprint server for biology·2026
Same author

"Where are They Now?": A Single Institution's 10-Years Experience with an Integrated Nuclear Radiology Fellowship.

Academic radiology·2026
Same author

Correction: Acalculous cholecystitis- an imaging and therapeutic update.

Abdominal radiology (New York)·2026
Same author

Prospective exploratory pilot study of 18 F-FMISO PET/CT for assessing tumor hypoxia in soft tissue sarcomas.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same author

A Call for High-Level Evidence Before Routine Implementation of Posttreatment SPECT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Response to the Comment on "Negative 18F-FES PET/CT Despite Estrogen Receptor Positivity By Immunohistochemistry."

Clinical nuclear medicine·2026
Same journal

Letter from the Editors.

Seminars in nuclear medicine·2026
Same journal

Expanding Horizons: The Role of Kaleidoscope and Relevant Images in Seminars in Nuclear Medicine.

Seminars in nuclear medicine·2026
Same journal

The diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma - A systematic review and meta-analysis.

Seminars in nuclear medicine·2026
Same journal

Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies.

Seminars in nuclear medicine·2026
Same journal

<sup>18</sup>F-FDG -PET/CT in cardiac sarcoidosis: Diagnosis, therapy monitoring, and future directions.

Seminars in nuclear medicine·2026
Same journal

Maximizing diagnostic yield: A systematic review and deep dive into PSMA PET scan protocol variations for prostate cancer.

Seminars in nuclear medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2025

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography
09:57

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

Published on: January 11, 2020

7.4K

Update on 18F-Fluoroestradiol.

Sophia R O'Brien1, Christine E Edmonds2, Rebecca E Ward3

  • 1Division of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA; Department of Radiology, Division of Breast Imaging, Hospital of the University of Pennsylvania, Philadelphia, PA.

Seminars in Nuclear Medicine
|October 5, 2024
PubMed
Summary
This summary is machine-generated.

18F-16α-Fluoroestradiol (18F-FES) PET/CT imaging is approved for ER+ metastatic breast cancer. It identifies patients likely to respond to endocrine therapy, guiding treatment decisions and improving patient outcomes.

More Related Videos

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

3.1K
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

11.9K

Related Experiment Videos

Last Updated: Jun 11, 2025

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography
09:57

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

Published on: January 11, 2020

7.4K
Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

3.1K
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

11.9K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiochemistry

Background:

  • 18F-16α-Fluoroestradiol (18F-FES) is an estrogen analogue used in Positron Emission Tomography (PET) imaging.
  • It targets the estrogen receptor (ER) in ER-expressing cells, correlating with biopsy-assessed ER status.

Purpose of the Study:

  • To review the foundational principles of 18F-FES imaging.
  • To describe current clinical applications and emerging research for 18F-FES PET/CT in breast cancer and other conditions.

Main Methods:

  • Review of proof-of-concept studies demonstrating 18F-FES PET/CT correlation with ER status.
  • Analysis of clinical approval timelines and SNMMI Appropriate Use Criteria (2023).

Main Results:

  • 18F-FES PET/CT is approved in the US and France for ER+ metastatic or recurrent breast cancer.
  • It serves as a biomarker to predict response to endocrine therapy.
  • SNMMI identified four appropriate indications for 18F-FES PET/CT use.

Conclusions:

  • 18F-FES PET/CT is a valuable tool for assessing ER status in breast cancer patients.
  • Its use guides endocrine therapy selection and aids in disease management.
  • Ongoing research explores broader applications beyond breast cancer.